New Approval Helps Implanting Propel Mini a Little Bit Easier
Intersect ENT has received a nod from FDA for a new delivery system to use for its sinus implant. The Menlo Park, CA-based company said the approval was for its Straight Delivery System for use to place the Propel Mini steroid releasing sinus implant in the ethmoid sinus.
PROPEL Mini helps maintain the sinus opening while delivering mometasone furoate directly where it is needed, improving outcomes of frontal (behind the forehead) and ethmoid (behind the bridge of the nose) sinus surgery. The new SDS is designed to help physicians achieve precise and easy delivery of the PROPEL Mini implant to the ethmoid sinus. The compan...
Source: MDDI - July 29, 2019 Category: Medical Devices Authors: MDDI Staff Tags: Implants Source Type: news
FDA Issues Complete Response Letter for Ryaltris NDA
June 25, 2019 -- Glenmark Pharma on Saturday said the US Food and Drug Administration (USFDA) has issued a Complete Response Letter (CRL) regarding the new drug application for Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 25, 2019 Category: Drugs & Pharmacology Source Type: news
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate, delivered with the dose-confirming Breezhaler® inhalation device, was presented at the 2019 annual international congress of the American Thoracic Society (ATS). (Source: World Pharma News)
Source: World Pharma News - May 22, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma
MONDAY, May 20, 2019 -- For patients with mild asthma with a low sputum eosinophil level, outcomes do not differ significantly for mometasone or tiotropium versus placebo; and budesonide-formoterol is superior to albuterol for prevention of asthma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 20, 2019 Category: Pharmaceuticals Source Type: news
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
The study of Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg] nasal spray) in pediatric patients aged 6 to under 12 years of age met its primary endpoint, and results were consistent with extensive clinical trial experience wit... Biopharmaceuticals Glenmark Pharmaceuticals, Ryaltris, olopatadine, seasonal allergic rhinitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2019 Category: Pharmaceuticals Source Type: news
Asmanex Twisthaler (Mometasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2019 Category: Drugs & Pharmacology Source Type: news
Asmanex Twisthaler (Mometasone Furoate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2019 Category: Drugs & Pharmacology Source Type: news
mometasone furoate (Nasonex)
Title: mometasone furoate (Nasonex)Category: MedicationsCreated: 6/6/1999 12:00:00 AMLast Editorial Review: 3/25/2019 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - March 25, 2019 Category: Allergy & Immunology Source Type: news
Intersect ENT launches trial of drug-coated sinus balloon
Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon.
The Menlo Park, Calif.-based company’s device is designed to deliver mometasone furoate directly to a person’s sinuses at the time of dilation.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT launches trial of drug-coated sinus balloon appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Otolaryngology Ear, Nose & Throat Pharmaceuticals Wall Street Beat intersectent Source Type: news
How Can Nanotechnologies Aid Implantable Drug-Delivery Systems?
Implantable technologies have come a long way over the years, and advancements in micro and nanotechnologies have helped device developers continue to push the envelope even further. Within the realm of drug delivery, advances in nanotechnologies have consistently improved patient outcomes by enabling sustained drug delivery to help treat chronic conditions. These scalable technologies have even offered localized drug delivery that can further improve bioavailability.
While many of these technologies offer a variety of opportunities, we’re still eagerly awaiting to see the impact of these advancements onc...
Source: MDDI - November 29, 2018 Category: Medical Devices Authors: Kristopher Sturgis Tags: BIOMEDevice San Jose Implants Source Type: news
Mometasone Furoate (Elocon) 0.1% Ointment (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 13, 2018 Category: Drugs & Pharmacology Source Type: news
Asmanex Twisthaler (Mometasone Furoate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2018 Category: Drugs & Pharmacology Source Type: news
Intersect ENT launches Sinuva steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) launched its steroid-releasing sinus implant, Sinuva, in the U.S. today. The company’s drug-eluting device is designed to treat nasal polyp disease in patients who have undergone previous sinus surgery.
Sinuva is placed during a routine doctor’s office visit and releases an anti-inflammatory steroid, mometasone furoate, directly to the patient’s nasal polyps for up to 90 days.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT launches Sinuva steroid-releasing sinus implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 2, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Implants Otolaryngology Ear, Nose & Throat Pharmaceuticals Regulatory/Compliance Wall Street Beat intersectent Source Type: news
Sinuva (Mometasone Furoate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2017 Category: Drugs & Pharmacology Source Type: news
Intersect ENT Announces FDA Approval of Sinuva (mometasone furoate) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
